MA40624A - Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant - Google Patents

Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant

Info

Publication number
MA40624A
MA40624A MA040624A MA40624A MA40624A MA 40624 A MA40624 A MA 40624A MA 040624 A MA040624 A MA 040624A MA 40624 A MA40624 A MA 40624A MA 40624 A MA40624 A MA 40624A
Authority
MA
Morocco
Prior art keywords
superior
papilloma virus
human papilloma
vaccine containing
virus antigens
Prior art date
Application number
MA040624A
Other languages
English (en)
Inventor
Viviana Giannino
Reinhard Glueck
Gaurav Gupta
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA40624A publication Critical patent/MA40624A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des gènes codant pour divers antigènes du papillomavirus de plusieurs sérotypes. Les gènes de la présente invention permettent de produire des particules de type virus présentant une amélioration en termes de qualité immunologique et de structure quaternaire. La présente invention concerne également une cellule hôte adaptée, de préférence
MA040624A 2014-09-11 2015-09-11 Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant MA40624A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2905MU2014 2014-09-11

Publications (1)

Publication Number Publication Date
MA40624A true MA40624A (fr) 2016-03-17

Family

ID=54843870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040624A MA40624A (fr) 2014-09-11 2015-09-11 Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant

Country Status (10)

Country Link
EP (1) EP3191505A2 (fr)
JP (1) JP2017528137A (fr)
CN (1) CN107002085A (fr)
AR (1) AR101840A1 (fr)
AU (1) AU2015313756A1 (fr)
BR (1) BR112017004181A2 (fr)
CA (1) CA2958222A1 (fr)
EA (1) EA201790365A1 (fr)
MA (1) MA40624A (fr)
WO (1) WO2016038625A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104845985B (zh) * 2014-02-18 2020-02-07 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
EP3365006A1 (fr) 2015-10-19 2018-08-29 Cadila Healthcare Limited Nouvel adjuvant et composition vaccinale le contenant
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
JP2021502822A (ja) * 2017-11-14 2021-02-04 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス
BR102020006846A2 (pt) * 2020-04-03 2021-12-07 Imunoscan Engenharia Molecular Ltda Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237224C (fr) * 1995-11-15 2006-06-27 Steven Ludmerer Particules synthetiques de type viral hpv11
EP0973546B1 (fr) * 1997-04-08 2004-03-17 Merck & Co., Inc. Formulations stabilisees du virus du papillome humain
ES2268787T3 (es) * 1997-09-05 2007-03-16 Medimmune, Inc. Metodo in vitro de desmontaje/embalaje de particulas similares a virus (vlp) de papilomavirus.
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CN101115766B (zh) * 2004-06-18 2013-05-08 印度免疫有限公司 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1
CN101487009B (zh) * 2008-01-15 2012-11-21 上海泽润生物科技有限公司 用毕赤酵母表达系统制备抗人乳头瘤病毒16型感染的疫苗的方法
MY182347A (en) * 2007-11-23 2021-01-20 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
JP6022159B2 (ja) * 2008-07-31 2016-11-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗ｈｐｖワクチン
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
AU2012255595A1 (en) * 2011-05-13 2013-12-12 Folia Biotech Inc. Virus-like particles and process for preparing same
KR102049988B1 (ko) * 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN103667319B (zh) * 2012-09-10 2017-09-26 同济大学 抗人乳头瘤病毒的三价疫苗及其制法和用途

Also Published As

Publication number Publication date
BR112017004181A2 (pt) 2017-12-05
CA2958222A1 (fr) 2016-03-17
EA201790365A1 (ru) 2017-07-31
WO2016038625A3 (fr) 2016-04-28
JP2017528137A (ja) 2017-09-28
CN107002085A (zh) 2017-08-01
AU2015313756A1 (en) 2017-03-09
WO2016038625A2 (fr) 2016-03-17
AR101840A1 (es) 2017-01-18
EP3191505A2 (fr) 2017-07-19

Similar Documents

Publication Publication Date Title
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
IL263818A (en) Antibodies against Zika virus and methods of use
WO2016090327A3 (fr) Anticorps ciblant l'antigène de maturation des lymphocytes b et procédés d'utilisation
MY181175A (en) Therapeutic hpv16 vaccines
TN2017000133A1 (en) Modified virus-like particles of cmv
TW201613963A (en) Anti-JAGGED1 antibodies and methods of use
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MA40624A (fr) Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2019004690A (es) Constructos de anticuerpos.
FI3355915T3 (fi) Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt
EP3515482A4 (fr) Association de nouveaux vaccins contre le virus zika et constructions d'anticorps anti-adn destinées à être utilisées contre le virus zika
WO2013188673A3 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
MX356325B (es) Composicion para cuidado personal.
SG11201912454SA (en) Virus-like particles comprising zika antigen
MX2017008286A (es) Nuevos metodos para el despliegue de peptidos ciclicos en particulas de bacteriofagos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EP3403671A4 (fr) Vaccin contenant des particules virales immobilisées
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
EP3170509A4 (fr) Vaccin contenant des particules pseudo-virales
WO2015196180A3 (fr) Vaccins contre la grippe et leurs procédés d'utilisation